Kangyuan Medical Completes Tens of Millions RMB Financing Led by Daotong Investment to Advance Innovative Selective Material Industrialization Platform

VCBeat has learned that Kangyuan Medical Technology (Dalian) Co., Ltd., a leading domestic enterprise in the industrialization platform for selective adsorption materials, recently announced the completion of a financing round amounting to tens of millions of yuan. This round was led by Daotong Investment. The funds raised will be primarily used for new product research and development, refinement of core technologies, and advancement of clinical trials for its products.

Kangyuan Medical Technology (Dalian) Co., Ltd. was established in November 2016. The company is a rare domestic industrialization platform for innovative selective materials, possessing full independent intellectual property rights. It has built a new-generation specific material technology platform centered on nanobodies, overcoming a series of key common technologies ranging from nanobody screening and mass production to the large-scale synthesis of specific biomedical adsorption materials, reaching an internationally advanced and domestically leading level. The company is recognized as a National High-Tech Enterprise, a National Intellectual Property Advantage Enterprise, and a Technology-Based Small and Medium-sized Enterprise by the Ministry of Science and Technology. It hosts a Postdoctoral Research Station, the Liaoning Provincial Engineering Research Center for Blood Purification Adsorption Materials, and is designated as a Liaoning Provincial New R&D Institution. The company has been honored with the Outstanding Enterprise Award in the Growth Category at the 11th China Innovation and Entrepreneurship Competition, and the Second Prize in the Growth Category at the 8th Dalian Innovation and Entrepreneurship Competition.

Selective materials are designed to achieve specific functions by engineering their structural design or functionalizing their surfaces, thereby enabling selective binding or isolation of target substances. With advantages such as high efficiency, precision, and safety, selective materials have been widely applied in various fields, including healthcare, pharmaceuticals, environmental protection, aerospace, new energy, and agriculture.Selective materials represent a blue-ocean market with trillion-dollar potential, high entry barriers, and high value-added technology.. Kangyuan Medical relies on Professor Jia Lingyun’s team from the School of Bioengineering at Dalian University of Technology in the fields of selective adsorption materials and selective coating materialsNearly Three Decades of Technological Accumulation, relying entirely onProprietary R&D, established two core technology platforms: the site-specific immobilization technology platform and the surface modification technology platform, thereby formingMore than ten proprietary product pipelines, all targeting white-space or blue-ocean markets where effective solutions are currently lacking or dominated by foreign monopolies。

The company's core technologies have been successfully implemented in multiple key scenarios.In the Medical Field, the company pioneered the application of nanobody technology in the field of selective adsorption materials, focusing on the treatment of critical conditions such as renal failure, hepatic failure, autoimmune diseases, and the removal of circulating cancer cells from the blood.Research and Development and Production of High-Precision Selective (Targeted) Blood Purification Adsorption Column-Related Products (Class III Medical Devices). It is reported that the company’s first adsorption column product has completed registration testing, animal studies, and clinical feasibility studies, and is currently in the phase of conducting pivotal clinical trials in collaboration with the Department of Critical Care Medicine at West China Hospital of Sichuan University, forA world-first and China-first milestone product in the field of precision blood purification. In the pharmaceutical field, in response to the high cost of imported core affinity chromatography consumables, domesticallyPioneered the development of affinity chromatography media for gene therapy vectors, this product achieves yields and purity comparable to those of imported products for gene therapy vectors across multiple serotypes, and is expected to help gene therapy companies reduce production costs and improve the accessibility of gene therapy technologies.

Recently, the Company has entered into a strategic cooperation agreement with Beijing Jinlan Technology Co., Ltd. to jointly promote the application of AAV broad-spectrum affinity chromatography media and columns, as well as the screening and quantitative preparation of specific nanobodies. This collaboration aims to advance the localization and scale-up of key downstream purification consumables for gene therapy, improve the yield efficiency of downstream purification processes for gene therapy drugs, and thereby further enhance the production capabilities of domestically manufactured gene therapy products and strengthen coordination across the upstream and downstream industry chains. In addition, both parties will engage in technical cooperation spanning multiple areas, including the screening, development, and preparation of AAV series products, as well as material synthesis services, to comprehensively accelerate the localization of critical consumables for gene therapy drugs and facilitate the industrial commercialization of gene therapies.

Regarding the closing of this round of financing,Wang Yumeng, General Manager of Kangyuan Medical, stated: We thank our investors for their trust and support. Kangyuan Medical will continue to deepen its engagement in the selective materials market, remain committed to its original mission of “addressing major national needs and promoting the commercialization of scientific and technological achievements,” expand the application areas and market reach of its core technologies, and strive to become a leading enterprise in specific adsorption materials with an international perspective. The company is dedicated to advancing the continuous regulatory approval and commercial deployment of next-generation high-efficiency adsorption materials that feature fully independent intellectual property rights and international competitiveness, while addressing urgent clinical and industrial needs.

Lin Zhencheng, Managing Director of Daotong Investment, statedSelective adsorption materials, as a blue-ocean market characterized by high barriers to entry and high technological value-added, represent a critical battleground for China’s advancement in scientific and technological innovation, enabling the nation to transition from “playing catch-up” to achieving “leapfrog development.” Leveraging the robust technological foundation of a national Double First-Class university, Kangyuan Medical has assembled a comprehensive industrialization team spanning from R&D specialists to industry professionals. The company has overcome multiple technical barriers, with its core technologies already deployed in various clinical and industrial scenarios where there is urgent demand. Its product portfolio features a well-structured short-, medium-, and long-term roadmap. We look forward to Kangyuan’s rapid growth in both product offerings and revenue, positioning it as the market leader in the field of selective adsorption materials.

Daotong Investment focuses on forward-looking medical innovation technologies and serves as the early-stage exclusive investor for multiple first-in-China technology projects. Its investment portfolio encompasses VC funds, as well as angel funds in the Yangtze River Delta and the Greater Bay Area. The core team hails from the healthcare industry, with a proven track record of incubating early-stage startups and founding and managing publicly listed companies with market capitalizations exceeding RMB 10 billion. Adhering to the philosophy of being not only a value discoverer but also a value creator, Daotong Investment has received numerous accolades, including Top 100 VC Firms and Top 20 Medical Device Investors by China Venture. Selected portfolio companies include Landin Medicine, Deepwise Healthcare, Hano Medical, Triastek, and Heyuan Biology.